Laufende klinische Studien
| Studie (Akronym) & Art der Studie | Sponsor/ Auftraggeber | Studienleitung/ SDP | Mitarbeiter (IBE) | Status |
|---|---|---|---|---|
| APART: Wirksamkeit des Affolter-Modells® bei Patienten mit Ataxie nach Schlaganfall: randomisierte, kontrollierte, verblindete klinische Studie im Parallelgruppendesign mit Messwiederholungen | Universität Augsburg | Prof. Dr. E. Grill Prof. Dr. A. Bender | Dr. R. Strobl | Protokollentwicklung |
| CML Absetzregister: Wissenschaftliches Register zur prospektiven Erfassung der therapiefreien Remission bei chronischer myeloischer Leukämie mit dem Ziel der Erforschung prognostischer Faktoren | Universität Heidelberg | Prof. Dr. S. Saußele | Prof. Dr. M. Pfirrmann A. Albeer | Rekrutierung |
| ESTIMATION: Efficacy of asciminib in chronic phase CML patients with T315I mutations | Friedrich-Schiller-Universität Jena | Prof. Dr. T. Ernst | Prof. Dr. M. Pfirrmann T. Brenninger-Lang | Protokollentwicklung |
| PROTAGORAS: PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS) | Klinikum der LMU | Prof. Dr. S. Massberg Prof. Dr. L. Weckbach | PD Dr. M. Lauseker-Hao Dr. Y. Xu | Rekrutierung |
| ARTIST: Risk-adapted frontline treatment with Asciminib | Friedrich-Schiller-Universität Jena | Prof. Dr. T. Ernst | Prof. Dr. M. Pfirrmann A. Albeer | Protokollentwicklung |
| ECWM-2: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia | Uniklinik Ulm | Prof. Dr. C. Buske | Prof. Dr. E. Hoster K. Gutmair | Auswertung |
| PLATO: Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients: a phase II trial of the European MCL Network | Klinikum der LMU | Dr. C. Schmidt | Prof. Dr. E. Hoster L. Jiang | Rekrutierung |
| EEN-RICH: A randomized, double-blind, placebo-controlled, phase I/II trial of multi-donor fecal microbiota transfer for maintenance of Remission after Induction treatment with Exclusive Enteral Nutrition (EEN) in CroHn’s disease (EEN-RICH study) | Klinikum der LMU - Dr. von Haunersches Kinderspital | PD Dr. T. Schwerd | Prof. Dr. E. Hoster L. Jiang | Rekrutierung |
| VIWA-1: Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia (VIWA-1) – a multicenter, randomized, explorative open label phase II international study | Uniklinik Ulm | Prof. Dr. C. Buske | Prof. Dr. E. Hoster | Rekrutierung |
| COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients – a multicenter open label single-arm phase II study | Uniklinik Ulm | Prof. Dr. C. Buske | Prof. Dr. E. Hoster | Rekrutierung |
| PRiSMA: Pädiatrisches Register für Schlaganfall als multidisziplinäre Ausgangsplattform fokussierter Forschung und Versorgung | Klinikum der LMU - Dr. von Haunersches Kinderspital | PD Dr. L. Gerstl | PD Dr. M. Lauseker-Hao J. Fusiak | Rekrutierung |
| PRIDE: PRotective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma | Klinikum der LMU | Prof. Dr. M. Niyazi | Prof. Dr. U. Mansmann | Rekrutierung |
| CARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B): a randomized phase II study | Klinikum der LMU - Med III | Prof. Dr. M. Dreyling | Prof. Dr. E. Hoster L. Jiang | Rekrutierung |
| MASPAC: MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) – a Randomized, Controlled Clinical Study | Klinikum der LMU | Prof. Dr. M. Niyazi | Prof. Dr. U. Mansmann M. Müller Dr. Y. Xu | Auswertung |
| EPIDAURUS: Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary intervention | Klinikum der LMU | PD Dr. K. Rizas | Prof. Dr. U. Mansmann | Rekrutierung |
| PROFIL: Effect of propionate supplementation as an anti-inflammation approach on neurofilaments in patients with corticobasal syndrome (CBS): Double-blind, randomized, placebo-controlled, parallel-group, phase II study | Klinikum der LMU - DSGZ | Prof. Dr. J. Levin | Prof. Dr. U. Mansmann | Rekrutierung |
| MCL Elderly III: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy | Uniklinik Mainz | Prof. Dr. G. Hess | Prof. Dr. E. Hoster L. Jiang | Rekrutierung |
| ALTERNATIVE-C: A prospective multicenter phase 2 study of the chemotherapy-free combination of the intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor Copanlisib in combination with Obinutuzumab in patients with previously untreated follicular lymphoma (FL) and a high tumor burden | Klinikum der LMU - Med III | Dr. C. Schmidt | Prof. Dr. E. Hoster Dr. V. Jurinovic | Auswertung |
| CZAR-1: Randomisierte Phase-3-Studie des European Consortium for Waldenström´s Macroglobulinemia zur Behandlung des Morbus Waldenström mit Ibrutinib mit oder ohne Carfilzomib | Uniklinik Ulm | Prof. Dr. C. Buske | Prof. Dr. E. Hoster | Rekrutierung |
| XVIR-01: Single center, open-label, phase I, dose finding and safety study on the oncolytic adenovirus XVir-N-31 in patients with recurrent glioblastoma (XVIR-01) | Goethe -Universität Frankfurt | Prof. Dr. J. P. Steinbach | PD Dr. M. Lauseker-Hao | Protokollentwicklung |
| PyloResPres: Pylorus resection versus pylorus preservation in pancreatoduodenectomy: A multicenter surgical registry-based randomized active-controlled trial (RRCT) from the German DGAV StuDoQ|Pancreas Registry | Klinikum der LMU | Prof. Dr. J. Werner | Dr. A. Crispin | Auswertung |
| PONTrack: Prospective, non-randomised, open-label, multicentre phase II trial of patients with CML treated with Ponatinib in order to assess MR4 achievement after 2 years of treatment | Universität Heidelberg | Prof. Dr. S. Saußele | Prof. Dr. M. Pfirrmann A. Albeer | Auswertung |
| FASCINATION: Prospective, non-randomised, open-label, multicentre phase II trial of patients with de novo BCR-ABL1 positive CML in chronic phase, treated with a combination of an established TKI and asciminib in order to assess impact on deep molecular response | Friedrich-Schiller-Universität Jena | Prof. Dr. T. Ernst | Prof. Dr. M. Pfirrmann T. Brenninger-Lang | Rekrutierung |
| BlastCrisis: European CML blast crisis registry for patients with CML in blast crisis | Friedrich-Schiller-Universität Jena | Dr. C. Fabisch PD Dr. A. Brioli PD Dr. M. Lauseker-Hao | PD Dr. M. Lauseker-Hao | Auswertung |
| TRACE: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific CD4+ and CD8+ T cells against AdV, CMV and EBV: A Phase III, prospective multicentre clinical trial. Multivirus-specific T-cell transfer post SCT vs AdV, CMV and EBV infections | Albert-Ludwigs-Universität Freiburg | Prof. Dr. T. Feuchtinger | Prof. Dr. M. Pfirrmann | Rekrutierung |
| MARTHA: Milk Against Respiratory Tract Infections and Asthma | Klinikum der LMU - Dr. von Haunersches Kinderspital | Prof. Dr. E. von Mutius | Prof. Dr. U. Mansmann | Rekrutierung |
| GABe2016: First line therapy of advanced stage follicular lymphoma in patients < 60 years not eligible for standard immunochemotherapy and all patients ≥ 60 years - Prospective randomized evaluation of single agent GA101 versus GA101 plus Bendamustine followed by GA101 | Klinikum der LMU | Prof. Dr. C. Buske | Prof. Dr. E. Hoster Dr. V. Jurinovic | Auswertung |
| RESIST: Optimization of individualized therapy for CRCs with secondary RESISTance towards anti-EGFR targeted therapy using an avatar model (Colon-Resist-Net) | Klinikum der LMU | Prof. Dr. S. Stintzing | Prof. Dr. U. Mansmann | Rekrutierung |
| NAUT: Multicenter Prospective Trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of Nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd time | Universität Heidelberg | Prof. Dr. S. Saußele | Prof. Dr. M. Pfirrmann A. Albeer | Rekrutierung |
| HyperTET: Trabectedin with Regional Hyperthermia as second line treatment for patients with advanced soft-tissue sarcoma | Klinikum der LMU - Med III/ Hyperthermie | Prof. Dr. R. Issels | Prof. Dr. U. Mansmann Dr. Y. Xu | Auswertung |
| TRIANGLE: Autologous transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle cell lymphoma –a randomized European mcl network trial | Klinikum der LMU - Med III | Prof. Dr. M. Dreyling | Prof. Dr. E. Hoster L. Jiang | Auswertung |